Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma

Table 1 Baseline analysis, n (%)

Factors		Patient group (n = 80)	Control group (n = 50)	χ2 /t	P value
Gender				0.264	0.609
	Male	50 (62.50)	29(58.00)
	Female	30 (37.50)	21 (42.00)
Age (yr)		54.6 ± 5.0	53.7 ± 4.1	1.068	0.288
BMI (kg/m2)		22.86 ± 1.93	23.17 ± 2.07	0.866	0.388
Past medical history
	Hypertension	25 (31.25)	10 (20.00)	1.979	0.160
	Hyperlipidemia	13 (16.25)	6 (12.00)	0.445	0.505
	Diabetes	20 (25.00)	10 (20.00)	0.433	0.510
Smoking history				0.081	0.776
	Yes	50 (62.50)	30 (60.00)
	No	30 (37.50)	20 (40.00)
History of alcoholism				0.494	0.482
	Yes	15 (18.75)	7 (14.00)
	No	65 (81.25)	43 (86.00)
Place of residence				0.177	0.674
	Urban area	45 (56.25)	30 (60.00)
	Rural area	35 (43.75)	20 (40.00)
Tumor size
	≥ 5 cm	45 (56.25)
	< 5 cm	35 (43.75)
Combined hepatitis
	Yes	70 (87.50)
	No	10 (12.50)
TNM staging
	Stage I+II	33 (41.25)
	Stage III+IV	47 (58.75)
Lymph node metastasis
	Yes	42 (52.50)
	No	38 (47.50)
Differentiation
	Low differentiation	27 (33.75)
	Moderate + high differentiation	53 (66.25)
AFP (ng/mL)				59.583	< 0.001
	≤ 200	25 (31.25)	50 (100.00)
	>200	55 (68.75)	0 (0.00)

BMI: Body mass index; AFP: Alpha fetoprotein; TNM: Tumor, node, metastasis.